N | 2936 |
Female | 2540 (86.5%) |
Age (years) | 44 (35–53) |
Body weight (kg) | 69 (59–82) |
Diagnosis | |
CLE | 278 (9.5%) |
cSLE | 275 (9.4%) |
SLE | 2383 (81.2%) |
Age at diagnosis (years) | 31 (23–40) |
Disease duration (years) | 9 (4–19) |
Organ involvement* | |
Skin | 1490 (50.7%) |
CNS | 561 (19.1%) |
Joints | 2115 (72.0%) |
Kidney | 803 (27.4%) |
Heart | 408 (13.9%) |
Lungs | 445 (15.2%) |
Corticosteroids | |
Systemic | 1089 (37.1%) |
Topical | 98 (3.3%) |
Immunosuppressants | |
MMF | 310 (10.6%) |
AZA | 289 (9.8%) |
MTX | 240 (8.2%) |
Other | 123 (4.2%) |
Antimalarials | |
Hydroxychloroquine | 1988 (67.7%) |
Chloroquine | 47 (1.6%) |
Mepacrine | 9 (0.3%) |
Biologicals | |
BLM | 84 (2.9%) |
RTX | 29 (1.0%) |
Other | 17 (0.6%) |
Values were calculated based on available data and are shown as N (%) or median (IQR).
*Reported by adult and childhood-onset SLE patients (CLE excluded).
AZA, azathioprine; BLM, belimumab; CLE, cutaneous lupus erythematosus; CNS, central nervous system; cSLE, childhood-onset SLE; MMF, mycophenolate mofetil; MTX, methotrexate; RTX, rituximab.